COST-UTILITY ANALYSIS OF NEOADJUVANT PERTUZUMAB AND TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY HER-2 POSITIVE BREAST CANCER

被引：0
|
作者：
Ignatyeva, V [1 ]
Khachatryan, G. [1 ]
机构：
[1] Russian Presidential Acad Natl Econ & Publ Adm, Moscow, Russia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN173
引用
收藏
页码：A739 / A740
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [2] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [3] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [4] Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
    Babigumira, Joseph B.
    Santos, Eduardo
    Antao, Vincent Percival
    Wang, Bruce
    Portera, Chia C.
    Kamath, Tripthi
    Garrison, Louis P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER
    Polanco, C.
    Carulla, M.
    Badia, X.
    Ramirez-Arellano, A.
    VALUE IN HEALTH, 2008, 11 (06) : A468 - A468
  • [6] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA
    Li, H.
    Guan, X.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Li, K.
    Liu, C.
    Chu, Y.
    Ma, A.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [7] Cost-utility of adjuvant trastuzumab in Her-2/neu positive breast cancer: A Canadian perspective
    Skedgel, C.
    Rayson, D.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL IN THE NEOADJUVANT TREATMENT OF WOMEN WITH HER2-POSITIVE, LOCALLY ADVANCED, INFLAMMATORY OR EARLY BREAST CANCER IN PORTUGAL
    Ribeiro, I
    Lourenco, O.
    Alves, C.
    Thuresson, P.
    Monteiroa, I
    Batel-Marques, F.
    VALUE IN HEALTH, 2016, 19 (07) : A736 - A737
  • [9] COST-UTILITY ANALYSIS OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY VERSUS TRASTUZUMAB AND CHEMOTHERAPY FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2+EARLY BREAST CANCER IN SPAIN
    Colomer, R.
    Arroyo, I
    Lopez, N.
    Gutierrez Nicolas, F.
    VALUE IN HEALTH, 2019, 22 : S458 - S459
  • [10] ECONOMIC EVALUATION OF PERTUZUMAB NEOADJUVANT TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED, INFLAMMATORY, OR EARLY STAGE HER2-POSITIVE BREAST CANCER IN GREECE
    Mylonas, C.
    Kourlaba, G.
    Skroumpelos, A.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A735 - A735
12345